Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.

ABSTRACT:

Background

Phase 3 clinical data has shown higher proportions of patients with objective response, longer response duration, and longer overall survival with nivolumab versus docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC). We aimed to evaluate the long-term benefit of nivolumab and the effect of response and disease control on subsequent survival.

Methods

We pooled data from four clinical studies of nivolumab in patients with previously treated NSCLC (CheckMate 017, 057, 063, and 003) to evaluate survival outcomes. Trials of nivolumab in the second-line or later setting with at least 4 years follow-up were included. Comparisons of nivolumab versus docetaxel included all randomised patients from the phase 3 CheckMate 017 and 057 stud

SUBMITTER: Antonia SJ 

PROVIDER: S-EPMC7193685 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature